Although formation of urothelial carcinoma of the bladder (UCB) requires multiple steps and proceeds along divergent pathways, the underlying genetic and molecular determinants for each step and pathway remain undefined. By developing transgenic mice expressing single or combinatorial genetic alterations in urothelium, we demonstrated here that overcoming oncogene-induced compensatory tumor barriers was critical for urothelial tumor initiation.
INTRODUCTION
Urothelial carcinoma of the bladder (UCB) is the fifth most common cancer globally and the costliest cancer to treat on a per-case basis [1] [2] [3] . UCB is not homogenous but consists of subtypes characterized by distinct phenotypes, clinical behaviors and genetic alterations [4] [5] [6] [7] [8] [9] [10] .
At presentation, 70-75% of the UCB are of low pathological grade, papillary-appearance and confined to the urothelial layer (e.g., pTaG1/2). While these tumors can be initially removed by transurethral resection, they frequently recur, thus requiring additional surgical procedures [11, 12] . Low-grade urothelial hyperplasias are believed to be the precursors of these tumors [13, 14] . Genetically, mutations of the components of the receptor tyrosine kinase (RTK)/Ras pathway are extremely prevalent in these tumors, with fibroblast growth factor receptor 3b mutated in 45-75% [15] [16] [17] [18] [19] , Ha-ras in 15-40% [10, 16] , PI-3-kinase in 25% [20] and Raf-1 in ~7% [21] of the tumors. Because most mutations affecting the different components of this pathway do not co-exist in a given tumor [22] , there is a strong reason to believe that mutations of this signaling pathway occur in at least 90% of the low-grade, papillary UCB. Also prevalent in this UCB subtype is the allelic loss of chromosome 9, occurring in over half of the cases [14, [23] [24] [25] .
The second major subtype of UCB accounts for 20-25% of all the UCB and presents as high-grade, invasive tumors (e.g., pT1-4). These tumors often assume a highly aggressive clinical course and, despite radical cystectomy and concurrent chemotherapy, about half of them advance to local and distant metastasis, for which the 5-year survival rate is only 36% and 6%, respectively [26] [27] [28] [29] . Patients with high-grade, invasive UCB usually do not have a prior history of low-grade, papillary UCB, and these two tumor subtypes therefore do not appear to be a continuum in tumor progression [4, 15, 16, 30] . Instead, the majority of the high-grade, invasive UCB are believed to derive from flat, high-grade carcinoma in situ (CIS) or arise de novo [31] .
Interestingly, mutations of the RTK/Ras pathway components, which occur in over 90% of the low-grade, papillary UCB, are relatively uncommon (<20%) in the high-grade, invasive UCB. In striking contrast, more than 50% of the high-grade, invasive UCB are associated with mutations and allelic loss of p53 and aberrant expression of retinoblastoma protein (pRb), events that are rare in low-grade, papillary UCB [32] [33] [34] [35] .
Aside from the two major UCB subtypes, a third, much less well-understood subtype, namely the high-grade, papillary UCB (e.g., pTaG3), has been suggested to exist. Although constituting ~3% of all the UCB, the high-grade papillary UCB presents a major challenge in clinical management [5, 36] . Associated with a high risk of progression to invasive UCB, these tumors are often managed with surgical resection plus local Bacillus Calmette-Guérin immunotherapy. When such therapy fails, radical cystectomy is the only remaining option. To date, the few studies that have analyzed the genetic alterations showed that these tumors harbor a significantly greater number of chromosomal abnormalities than the low-grade, papillary UCB, but much fewer chromosomal changes than the high-grade, invasive UCB [6, 37] . It remains an open question whether the high-grade, papillary UCB arise de novo or out-grow from the flat CIS lesion or have progressed from low-grade, papillary UCB.
Genetically engineered mice are excellent tools for dissecting the sequential steps of urothelial tumor formation and progression along the divergent phenotypic and genetic pathways. We previously showed that urothelial expression of a constitutively active Ha-ras in transgenic mice could elicit low-grade, papillary UCB that strongly resembled its human counterpart [38] . The tumor induction was, however, highly dependent on gene dosage, as only homozygous mice bearing two copies of the mutated Ha-ras transgene, but not the heterozygous mice bearing one copy of the same transgene, developed early-onset tumors (before 10 months of age) [38, 39] . Between 1-9 months of age, the heterozygous mice had persistent, low-grade urothelial hyperplasias that did not progress nor regress. This raised the possibility that one or more tumor barriers that had been established in response to Ras activation prevented urothelial tumor initiation. In another transgenic model, we showed that low-level expression of a Simian virus 40 large T antigen (SV40T) in urothelium elicited exclusively high-grade lesions that bore strong resemblance to flat CIS in humans [40] . Interestingly, these CIS-like lesions were also persistent without regression or progression until the mice reached beyond 10 months of age, at which point the CIS gradually evolved into high-grade, papillary UCB [41] . Therefore, data from both of these two transgenic models suggest that activated Ha-ras or SV40T alone at low gene dosages were insufficient to trigger early-onset UCB, and that collaborating genetic events are required to initiate UCB.
In the present study, we explored what specific tumor barriers might be present in the urothelial hyperplasias, precursors to the low-grade papillary UCB, in Ha-ras transgenic mice.
We tested whether Ras activation, prevalent in human low-grade, papillary UCB, was capable of interacting with deficiencies of p53 and pRb pathways, signatures of high-grade invasive UCB, in urothelial tumor initiation. Additionally, we investigated the key signaling molecules whose activation was associated with urothelial tumor formation. Finally, we evaluated the responses of urothelial tumor cells to therapeutic inhibitors and tested the concept that inhibiting multiple signaling targets had a better therapeutic effect than inhibiting a single target. Results from our studies have major implications on the combinatorial molecular events that are necessary to trigger UCB and the potential and challenges of pharmacological therapy of this disease.
MATERIALS AND METHODS

Single and Double Transgenic Mice
Transgenic mice expressing a constitutively active Ha-ras mutant (codon 61 (Q > L); abbreviated as Ras*) in urothelial cells under the control of a 3.6-kb murine uroplakin II (UPII) promoter were generated previously [38] . A heterozygous, low-copy line (one copy of UPIIRas* transgene per diploid genome) that reproducibly developed urothelial hyperplasias up to 10 months of age was chosen for this study. Another heterozygous, low-copy transgenic line specifically expressed a Simian virus 40 large T antigen (SV40T) in urothelial cells under the control of the same UPII promoter (UPII-SV40T), and reproducibly developed high-grade, carcinoma in situ throughout the urothelium [40, 41] . Both lines were originally produced and had since been maintained in an in-bred, FVB/N background in a specific pathogen-free facility.
Seven to eight week-old male and female mice from the two lines were cross-bred to produce double transgenic mice harboring both the UPII-Ras* and the UPII-SV40T transgenes.
Identification of single and double transgenic offspring was carried out by Southern blotting of NcoI-digested tail genomic DNAs using a probe situated at the 3'-end of the UPII promoter. The probe allowed the detection of restriction fragments representing the UPII-Ras* transgene (1.7-kb), the UPII-SV40T transgene (2.7-kb) and the endogenous UPII gene (1.4-kb). All animal studies were conducted in accordance with government guidelines and under an active protocol approved by the Institutional Animal Care and Use Committee (IACUC).
RT-PCR and Real-time PCR
The expression of Ras* and/or SV40T in urothelial cells at the mRNA level was verified by RT-PCR. Briefly, urinary bladders freshly dissected out of wild-type, single and double transgenic mice were inverted inside out and their urothelial cells scrapped off using a chemical weighing spatula. After extraction of total RNA using an RNA extraction kit (Invitrogen), reverse transcription and synthesis of the second strand cDNA were performed and the doublestranded cDNAs were used as a template for PCR. Oligonucleotide primer pairs used were: (i) for Ras* transgene (e.g., rabbit Ras*): forward, 5'-CTAACCAACCCCCTCCTCTC-3', and reverse, 5'-ATTCGTCCACGAAGTGGTTC-3'; (ii) for control endogenous Ras (e.g., mouse for 15", 55°C to 58°C for 20" and 72°C for 30" for 50 cycles. Amplification of mouse ß-actin was carried out in parallel for each sample and used as an internal reference.
Cell Cycle Distribution
Urinary bladders from 3-week old mice were inverted inside out and the mucosa was incubated in ice-cold phosphate-buffer saline (PBS) containing 1 mg/ml dispase at 4°C overnight. Bladder mucosa was then gently scraped off, washed with PBS and digested with a 0.2% Trypsin-EDTA solution at 37°C for 30'. After centrifugation, the pellet containing urothelial cells were resuspended in fresh Trpsin-EDTA solution and incubated for another 30'.
The digestion mixture was supplemented with fetal bovine serum to a finial concentration of 20%. The urothelial cells were collected by centrifugation at 800 x g for 5', washed twice with ice-cold PBS, re-suspended in PBS and filtered through a 100-μM pore-size filter. The cells were then fixed with pre-cooled ethanol at 4°C overnight and stained with a solution containing 40 μg/ml propidium iodide and 100 μg/ml RNase. The stained cells were sorted with Facscan (Beckman), and the data were analyzed by ModFit LT 3.2 software (Verity Software House).
Ras Activity Assay
The Ras activity in urothelial cells derived from the various transgenic strains (n=8/strain) was determined using an in vitro Ras activation assay kit (Millipore). Briefly, urothelial cells were treated with a lysis buffer containing 25 mM HEPES (pH 7.5), 150 mM NaCl, 1% IGEPAL ® CA-630 (Sigma), 10 mM MgCl 2 , 1 mM EDTA and 2% glycerol, and the protein concentration of total urothelial proteins was determined using a BCA protein assay kit (Pierce). The urothelial proteins were then incubated with a Raf-1-RBD-GST fusion protein ("Raf-1-RBD" represents Ras binding domain of Raf-1 that specifically binds Ras-GTP; GST represents glutathione transferase). The mixture was then added into a glutathione-coated plate.
After washing, an anti-pan-Ras antibody was added, followed by a secondary antibody conjugated with horseradish peroxidase. After additional washing, the reaction was developed by the addition of 3,3'5,5'tetramethylbenzidine (Sigma) and read at 450 nm on a spectrophotometer.
In vivo Administration of Signaling Pathway Inhibitors
All the inhibitors used in this study were administered into the mice via intraperitoneal injection and with one dose every two days. Treatment commenced immediately after the mice were weaned (3 weeks of age), and lasted for 2 weeks in the case of the single-agent rapamycin treatment of rapamycin or for as long as the mice lived for multi-agent treatment to compare survival. All agents were freshly prepared in 50% DMSO in phosphate-buffer saline. Rapamycin (LC Laboratories), a selective mTOR inhibitor [42] , was reconstituted to a final concentration of 5 mg/ml and delivered at a dose of 10 mg/kg body weight per injection. UO126 (LC Laboratories), a phosphorylated MAPK inhibitor [43] , was reconstituted to a final concentration of 15mg/ml and delivered at a dose of 30 mg/kg body weight per injection. S3I-201(Calbiochem), a STAT3 inhibitor [44] , was reconstituted to a final concentration of 2.5 mg/ml and delivered at a dose of 5mg/kg per injection.
Western Blotting Analysis
Western blotting was carried out routinely using as starting material total urothelial proteins prepared in a 20 mM Tris-HCl buffer (pH 7.5) containing 10% SDS, 50 mM NaCl, 5 
Histopathology and Immunohistochemistry
Urinary bladders were fixed in PBS-buffered, 10% formalin and processed routinely for H&E staining for histopathological examination. For antibody labeling, deparaffinized sections were microwaved at maximal power setting in citrate buffer (pH 6.0) for 20 min for antigen unmasking, followed by consecutive incubation in solutions containing properly diluted primary and peroxidase-coupled secondary antibodies. The reactions were developed in a solution containing 3,3'-diaminobenzidine tetrahydrochloride and hydrogen peroxide. In addition to the primary antibodies used for Western blotting, the following were also used for immunohistochemistry: anti-keratin 14 (Covance), anti-pan Ras (Quality Biotech), anti-SV40T
(a gift from Dr. Douglas Hanahan of University of California, San Francisco).
Statistical Analyses
Student's t-test was used to compare the differences among the experimental groups using web-based SPSS package. A P value <0.05 was considered statistically significant. For multi-group comparisons, Mann-Whitney U test was employed using Web-based "Statext"
RESULTS
Presence of Multiple Tumor Barriers in Ras*-elicited Urothelial Hyperplasia
One of the interesting phenomena we observed with our heterozygous UPII-Ras* transgenic mice, which expressed a constitutively active Ha-Ras* oncogene in the urothelium, was the persistence of urothelial hyperplasia. Comprised of conspicuously thickened cell layers with little nuclear atypia and no loss in urothelial polarity (Fig. 1A) , these hyperplastic lesions persisted, but failed to advance to tumors over an extended (e.g., 10-month) period. We Fig. 2A and 2B ). While Ras* and SV40T single transgenics were fully viable and had bladders the sizes of those of the wild-type counterparts, the double transgenics had extremely rapid-growing tumors that occupied the entire bladders that were about 20 times heavier than those of the single transgenics ( Fig. 2C and 2D ). In the single transgenics, obstructive uropathy and hydronephrosis never occurred before 10 months of age; these abnormalities developed in 100% of the double transgenics by 5-7 weeks of age (Fig. 2C , lower panel; and data not shown). Because of the obstructive uropathy, all the double transgenics succumbed to death by week 9.
Microscopically, the Ras* single transgenics had normal-appearing urothelium at birth which evolved into simple hyperplasia that persisted throughout the 7-week observation period for this cohort ( Fig. 3A ; The hyperplasia could persist for up to 10 months in cohorts of longerobservation). The SV40T single transgenics exhibited urothelial dysplasia at birth and then high-grade flat lesions (in distended bladders) that resembled carcinoma in situ between 3-7 weeks of age (Fig. 3A) . Nuclear irregularity, pleomorphism, giant nuclei, chromatic condensation and mitotic figures, which were absent in the Ras* single transgenics, were common in the SV40T single transgenics. Consistent with the gross anatomy, neither Ras* nor SV40T single transgenics had any microscopic tumor in the bladder by week 7 in this cohort (and by 10 months in cohorts of longer observation). In stark contrast, the Ras*/SV40T double transgenics began with much thickened dysplastic urothelia/CIS at birth, and tumors emerged quickly by as early as week 3. The tumors were of high pathological grade, with large nuclear/cytoplasmic ratio, frequent mitotic figures, and conspicuous nucleoli. They had a papillary appearance and remained non-invasive by the time the double transgenics died of obstructive uropathy. Serial sections followed by immunohistochemical staining with an antibody against keratin 14, an epithelial marker specific for basal urothelial cells [52] , and antibodies against pan Ras and SV40T did not detect any tumor cell breaching the basement membrane (Fig. 3B) . These results demonstrated a strong synergistic effect between SV40T and Ras* in initiating high-grade urothelial carcinomas, and suggested that inactivation of both the p53 pathway and pRb family proteins plays a crucial role in allowing activated Ras* to overcome the tumor barriers.
Defective G1/S Checkpoint and Over-activation of Ras-GTPase and AKT-mTOR Pathway in Ras*/SV40T Double Transgenic Mice
The cell-cycle distribution of urothelial cells from each of the 4 mouse strains under study was considerably different. At the steady state, the overwhelming majority of the normal urothelial cells from the wild-type mice were quiescent and partitioned in the G0/G1 phase ( (Fig. 4C) .
Finally, urothelial cells expressing both oncogenes had activation in MAPK as well as AKT pathways, again suggesting a collaborative effect.
Inhibition of AKT-mTOR Signaling by Rapamycin Reduced Tumor Size but Hyperactivated the MAPK Pathway
To further examine the role of AKT-mTOR pathway activation in urothelial tumorigenesis and to determine whether inhibition of this pathway was sufficient to control highgrade urothelial carcinomas, we treated the double transgenics with rapamycin, an mTOR inhibitor [42, 57] . Three-week old, Ras*/SV40T double transgenics were randomized into two groups (8 mice/group), one group receiving solvent (50% DMSO) only, and another group receiving the solvent containing 5 mg/ml rapamycin, both administered intraperitoneally every two days. Two weeks later, the mice in both groups were sacrificed and their bladder tumors procured. A significant reduction of the tumor size in the treated group as reflected in reduced bladder weights was observed (Fig. 5A ). Rapamycin-treated mice had bladder weights of about 0.1 gram, compared to 0.6 gram in untreated mice (Fig. 5A, lower panel) . This corresponded well with a significant reduction in the number of tumor cells histologically (Fig. 5B) . No significance reduction in the body weights between the two groups was noted (Fig. 5A, lower panel), suggesting that at the dosage and time frame employed, rapamycin had minimum systemic toxicity. Despite the reduction in bladder weights, considerable number of tumor cells remained microscopically in the treated mice (Fig. 5B) . Rapamycin also did not reduce the pathological grade of the tumor cells (Fig. 5B) Molecularly, rapamycin treatment was effective, as expected, in decreasing the levels of phosphorylated mTOR and its downstream effector, S6 (Fig. 5C ). It did not affect the upstream acting phosphorylated AKT, suggesting that the rapamycin-mediated effects on AKT may be context-and tumor cell type-dependent [58] [59] [60] [61] [62] . Rapamycin, however, was not confined to inhibiting mTOR, as it completely inhibited phosphorylated p38 as well. This is in agreement with data from other studies involving rapamycin treatment [63, 64] . Whether inhibition of S6 led to the inhibition of p38 phosphorylation, as previously suggested [64] , remains to be seen.
Nevertheless, phosphorylated STAT3 was unaffected by the treatment. Surprisingly, rapamycintreated bladder tumors had a marked increase of phosphorylated MAPK, compared to solventtreated controls (Fig. 5C and 5D ). This suggested that AKT-mTOR pathway inhibition by rapamycin could lead to a hyper-activation of another signaling pathway and that, as a singleagent, rapamycin could be ineffective in long-term treatment of certain subtypes of bladder tumors.
Improved Survival via Multi-pathway Inhibition in Mice Bearing Rapid-growing
Urothelial Carcinomas
The initial results from the rapamycin experiment prompted us to examine whether inhibition of multiple signaling targets that were activated in the Ras*/SV40T double transgenics would be more efficacious than inhibiting a single target. Because rapamycin led to a marked, compensatory induction of MAPK signaling and because the STAT3 activity was not detectably inhibited by rapamycin, we added to the single agent regimen a specific inhibitor for phosphorylated MAPK (UO126; abbreviated as MAPK-i; [43] ), and a specific inhibitor for STAT3 (S3I-201; abbreviated as STAT3-i; [44] ). Ras*/SV40T double transgenics were randomized into three groups (8 mice/group) to receive (i) solvent (50% DMSO) only; (ii) solvent containing (5 mg/ml) of rapamycin; and (iii) solvent containing 5 mg/ml of rapamycin, 15 mg/ml of MAPK-i, and 2.5 mg/ml of STAT3-i (Fig. 6A) . Intraperitoneal delivery of the agents (every two days) commenced at 3 weeks of age and continued for 4 weeks after which all animals were sacrificed and their bladders weighed. The bladders of mice receiving the triple agents were significantly smaller and weighed less than those of the single-agent-treated mice (p<0.01) (Fig. 6A) . Another cohort comprising the three treatment groups (n=20/group) was then followed to compare the time of survival (Fig. 6B) . The untreated mice only survived 63 days, compared to the rapamycin-treated mice which survived 77 days. In contrast, the triple-agenttreated mice survived up to 119 days, an improvement of 42 days over the single-agent group and 56 days (e.g., almost doubling of survival time) over the untreated group (Fig. 6B) . The combination therapy, however, did not eradicate the bladder tumors, as all the treated mice eventually succumbed to obstructive uropathy. Western blotting and immunohistochemistry
showed that all the three intended targets, e.g., phosphorylated mTOR, MAPK and STAT3, were effectively inhibited ( Fig. 6C and 6D ). The failure to completely eliminate the tumors in our mice even with the three-agent regimen might therefore have to do the compensatory action of other signaling pathway(s). It might also be due to the fact that the treatment might have not begun soon enough, e.g., at 3 weeks of age when the tumors were already full-blown. it will be of interest to see if the cooperative events for these genes share certain commonalities.
DISCUSSION
Genetic Events Capable of Cooperating with Activated Ras in Initiating UCB
Indeed, we previously showed that SV40T was capable of cooperating with over-expressed EGFR in converting SV40T-induced CIS to high-grade, papillary UCB [68] . Whether SV40T has the same effect on mutated FGFR3b remains unknown, and is worthy of exploration.
On a cellular and molecular level, activated Ras and SV40T cooperate in multiple ways
to drive urothelial tumorigenesis. First, activated Ras creates significant replicative pressure on urothelial cells, leading to double strand DNA breaks, particularly in common fragile sites [70] .
Indeed, the number of apurinic and apyrimidinic sites and the level of histone H2A-x, markers of DNA damage, were both elevated in mutant Ras-induced urothelial hyperplasias (Zhou, H.-P., and Wu, X.-R., unpublished data). In response to the DNA damage, urothelial cells increase the synthesis of p53 which plays a principal role in DNA damage repair [71] . A new damage/repair balance might be reached that allows urothelial hyperplasias to persist without progression (Fig.   1 ). In the presence of SV40T, however, p53 is functionally impaired (Fig. 4A) and as a result mutant Ras-caused DNA damage cannot be promptly repaired, leading to increased genome instability. Unchecked genome instability is a prerequisite to tumorigenesis [72, 73] . Second, while mutated Ras is a strong mitogenic signal for urothelial cells, the G1/S restriction point in the Ras-expressing cells is intact via the overexpression of wild-type p53 (Fig. 1) , which holds urothelial proliferation in check. On the other hand, although SV40T-expressing urothelial cells have a defective G1/S checkpoint, the urothelium remains arrested at a CIS stage due to the absence of a strong mitogenic signal ( Fig. 3; [41] ). The co-presence of a potent mitogenic signal (mutated Ras) and defective cell-cycle checkpoint (enabled by SV40T) allows for efficient urothelial tumorigenesis. Third, while mutated Ras is known to up-regulate Ras-GTPase, SV40T
also has such an effect as shown in Fig. 4B and by others previously [55, 56] . The expression of these two genes is therefore additive, if not synergistic, in raising the Ras-GTPase level in the urothelium. Finally, mutant Ras and SV40T cooperate by activating both MAPK and AKTmTOR pathways (Fig. 4) . Mutant Ras alone primarily activated the MAPK pathway, whereas SV40T mainly activated the AKT-mTOR pathway. The latter may be related to the fact that under normal circumstances p53 upregulates PTEN, a potent upstream inhibitor of PI3K-AKT signaling axis [74, 75] , and that such an inhibitory effect is compromised by SV40T-mediated inactivation of p53 (Fig. 4A) . Expression of mutant Ras and SV40T transgenes is therefore necessary to activate both MAPK and AKT-mTOR signaling, consistent with findings in other tumor types [76, 77] .
Potential Origins of High-grade Papillary UCB
High-grade papillary UCB is a clinically important but biologically enigmatic entity whose cell origin and mode of progression remain uncertain [5, 36, 37] . The mutant Ras/SV40T 3 ). It is possible that this lack of detectable invasion results from premature death of the mice due to f renal failure. One also cannot completely rule out the possibility that molecular events critical for triggering invasion are absent in the mutant Ras/SV40T mice.
Targeted Therapy of UCB: the Effectiveness of Single Agent versus Multiple Agents
The current mainstay for treating high-grade, papillary UCB is local resection followed by intra-vesicle instillation of bacillus Calmette-Guérin (BCG) [5, 78] . If tumors are resistant to this treatment modality and progress to the invasive stage, they have to be treated with radical cystectomy, which nonetheless does not assure cure. The limited treatment options for different subtypes of UCB, in particular high-grade tumors, call for new therapeutic strategies. As the molecular details underlying the development and progression of UCB start to be unraveled, it is more possible than ever to devise targeted therapies for this disease [16] . In the present study, we found that inhibition of mTOR, a downstream effector of AKT, by a two-week course of rapamycin significantly reduces the size of high-grade, papillary UCB (Fig. 5) . However, considerable residual tumors exist and consequently the survival of the mice with these tumors did not significantly improve. Molecular analysis revealed a marked induction of activated MAPK in rapamycin-treated tumors (Fig. 5 ), suggesting this as a possible reason for the ineffectiveness of the single agent therapy. Additionally, compared to the wild-type mouse urothelial cells, those of the transgenic mice particularly the double transgenics had markedly activated STAT3, which was virtually unaffected by rapamycin treatment alone. A combination of three agents was then employed that contained inhibitors specific mTOR, MAPK and STAT3.
This led to significantly greater tumor inhibition and longer survival of the treated mice, compared to rapamycin as a single agent (Fig. 6 ). Our data suggest that a single agent targeting one pathway signal could result in a compensatory activation of another signaling pathway, causing drug resistance, and that sustained tumor control might be achievable through the inhibition of several targets in multiple signaling pathways.
We believe that the principle we have demonstrated with mouse models have significant implications on the rational design of targeted therapies for patients with bladder cancer.
Mounting evidence indicates that the PI3K-AKT-mTOR pathway is activated in a sizable portion of human bladder cancer, in particular high-grade and late-stage tumors. One recent study found phosphorylated mTOR and S6 in 74% and 55%, respectively, of muscle-invasive tumors [79] .
Activation of this pathway could be mediated by a range of abnormalities in its components including PTEN (e.g., by deletion, mutation or reduced expression), PI3K (by mutation) and AKT (by mutation or increased phosphorylation), all of which have been found in human bladder cancer [80] [81] [82] . It is to no great surprise that exposure of cell lines derived from human bladder cancer to rapamycin or other mTOR inhibitors results in inhibition of cell proliferation in vitro and reduced tumor growth in xenograft models [79, 83, 84] . Although much less is known about exactly how MAPK or STAT3 activation contributes to bladder cancer development and progression, evidence is emerging that these two signals are also frequently overexpressed and/or activated in human bladder cancer [85] [86] [87] [88] [89] . Because of the existence of non-overlapping effects of mTOR, MAPK and STAT3 and the extensive cross-talk among the different pathways, it is conceivable that the effective control of human bladder cancer with targeted therapies would also reply on the inhibition of multiple signaling pathways.
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